Clinical study demonstrates proof-of-concept for active personalized immunotherapy approach in a pioneering multi-center, multi-national study to treat brain cancer.
This study is a blueprint for Immatics’ highly personalized ACTolog® adoptive cell therapy trial currently treating patients at MD Anderson Cancer Center.